Is it worth investing?
Pfizer Inc is a middle-of-the-road business, at a price that demands patience.
$25.60
+16.80% over 12 months
Last updated: iun. 10, 2026
Financial summary
The reported figures, before any interpretation
Price and Trading
- Open The price at which Pfizer Inc shares first traded in the latest session.
- Close The price of the last Pfizer Inc trade in the session that closed.
- Day range The lowest and highest price Pfizer Inc shares reached in that session.
- Volume How many Pfizer Inc shares changed hands in the latest session.
- 52-week range The lowest and highest price of Pfizer Inc shares over the past year.
- Position in the 52-week range Where the current price of Pfizer Inc shares sits between the low and the high of the past year. 100% means right at the high.
- 50-day average The average price of Pfizer Inc shares over the last 50 sessions. Shows the short-term trend.
- 200-day average The average price of Pfizer Inc shares over the last 200 sessions. Shows the long-term trend.
- Market cap The market value of all Pfizer Inc shares combined.
Earnings and Valuation
- Earnings per share How much net profit belongs to a single Pfizer Inc share over the last twelve months.
- Estimated earnings, current year The earnings per share analysts expect from Pfizer Inc for the current financial year.
- Estimated earnings, next year The earnings per share expected from Pfizer Inc for the following financial year.
- Revenue per share How much of the annual sales of Pfizer Inc belongs to a single share.
- Book value per share How much Pfizer Inc equity belongs to one share, once debt is subtracted from assets.
- Revenue, last 12 months Total Pfizer Inc sales across the last four reported quarters.
- Price / earnings How many years of current profit a Pfizer Inc share costs at today price.
- Forward price / earnings The same ratio, but against the profit Pfizer Inc is expected to make next year.
- PEG The price/earnings ratio of Pfizer Inc divided by its growth rate. Below 1 is considered cheap relative to how fast it grows.
- Enterprise value / EBITDA The price of the whole Pfizer Inc business, debt included, against operating profit before depreciation.
Return and Risk
Moderate risk · 65- Net margin How much net profit Pfizer Inc keeps out of every unit of sales.
- Return on equity How much net profit Pfizer Inc produces from shareholder money.
- Dividend yield How much Pfizer Inc pays out in dividends each year, relative to the share price.
- Dividend per share The estimated annual amount received for each Pfizer Inc share held.
- Payout ratio What share of Pfizer Inc profit goes back to shareholders as dividends. The rest stays in the company.
- Beta How strongly Pfizer Inc shares move against the market. 1 means the same, above 1 means wider swings.
- Debt / equity How much debt Pfizer Inc carries for every unit of equity.
- Short interest as % of float What share of freely tradable Pfizer Inc stock is sold short, as a bet on a decline.
- Days to cover short positions How many normal trading days it would take to close every short position on Pfizer Inc.
Some values update after the trading session opens, others are recalculated after it closes. Figures from the financial statements change only when results are published.
Analyst consensus
What the 25 analysts covering the company think
Buy
- Strong sell 1 4%
- Sell 0 0%
- Hold 15 60%
- Buy 2 8%
- Strong buy 7 28%
The analyst consensus is in line with our score.
Analyst estimates, third-party source. These are not our verdict.
Price target
Where analysts see the price twelve months out
$29.19
+14.01% against today price
52-week low $21.55
52-week high $28.28
target $29.19
today $25.60
Rise from the low of the past year
+18.77%
Fall from the high of the past year
-9.49%
-
Price today $25.60
-
Revisions, last 30 days 12 ↑8 ↓
-
Expected earnings growth -4.21%
-
Analysts covering 25
Analyst estimates, third-party source.
Fundamentals
42.2
What the balance sheet and income statement say
Weak
- Piotroski F-score Nine tests of financial health, compared with last year. Above 7 means Pfizer Inc is improving.
- Mohanram G-score Eight tests for growth companies: research spending, stable margins, cash above accounting profit. Applied to Pfizer Inc.
- Cash operating profitability How much operating cash Pfizer Inc draws from its assets, before accounting adjustments.
- Asset turnover How much in sales Pfizer Inc generates from every unit of assets.
Return on capital is slowing
The business creates value above its cost of capital
Technicals
57.6
What the price chart says
Solid
- RSI (14 days) How fast the price of Pfizer Inc shares has risen recently. Above 70 means heavy buying, below 30 heavy selling.
- MACD histogram The gap between the fast and the slow trend at Pfizer Inc. Positive means the advance is accelerating.
- ADX (14 days) The strength of the trend at Pfizer Inc, whatever its direction. Above 25 means a clear trend.
- 12-month return, ex last month Classic momentum: the gain of Pfizer Inc shares over the past year, ignoring the last month.
Golden Cross active - the 50-day average is above the 200-day
Sentiment
64.5
Who holds the stock and what the market expects
Solid
- Institutional ownership What share of Pfizer Inc stock is held by funds and institutions.
- Insider ownership What share of Pfizer Inc stock is held by management and directors.
- Market sentiment The sentiment regime of the market Pfizer Inc trades in, inferred from market and credit indicators.
- Residual momentum The part of momentum in Pfizer Inc shares that remains once the market influence is removed.
The market is in a Risk-On regime
Short interest: Minimal
Safety
65.1
How far the company is from financial trouble
Solid
- Altman Z" The bankruptcy score for Pfizer Inc, in the variant that suits its sector. Above 2.6 means the safe zone.
- Distance to default How many standard deviations separate the value of Pfizer Inc from its debt threshold. More is better.
- Beneish M-score A detector of accounting manipulation. Below -1.78 means no signs appear at Pfizer Inc.
- Free cash flow coverage How many times the free cash flow of Pfizer Inc covers its payment obligations.
2 warnings, none serious
No signs of accounting manipulation
Who it suits
It depends what you are after
-
Investor over decades 43.2You buy and hold, whatever the cycle.
-
Cautious, you want safety 50.9The priority is not losing, rather than winning big.
-
Offensive, you want growth 47.7You accept volatility for a higher return.
-
Tactical, short term 45.4You move in and out on price and momentum signals.
Scores are close across lenses: the company reads the same whatever the investing style.
Risk
Falls harder than the market
55
resilience score, 17th percentile in the sector
- Crash-ul COVID-19, 2020 How much Pfizer Inc shares lost from the high reached to the low of that period.
- Bear market 2022 How much Pfizer Inc shares lost from the high reached to the low of that period.
- Held up better than Out of comparable companies, how many fell harder than Pfizer Inc in the same crises.
- Criză severă, stil 2008 (-40%) An estimate for Pfizer Inc under a severe market scenario. It is not a price forecast.
- Annual volatility How widely the price of Pfizer Inc shares swings over a year, measured statistically.
- Largest historical drawdown The deepest fall of Pfizer Inc shares from a high to the low that followed it, across the whole available history.
Verdict
Our verdict, from an automated analysis of over 400 indicators
60.5/100
Neutru
high confidence
Expensive
Balanced
Mixed
Pfizer Inc produces 6.77% on capital and pays 5.36% for it, for 15 years running. But the price today asks 19.48x earnings, and the growth rate has slowed to -14.56% a year.
Scores across the six pillarsprofitability
return on capital 6.77%The engine runs at middling speed
produces
6.77%
costs
5.36%
The gap of 1.41% has held in each of the last 15 years.
- net margin12.42%
- consecutive revenue growth15 years
valuation
price / earnings 19.48xThe price demands patience
19.48xprice / earnings
$8.70 – $56.36the range across 6 methods
The 6 methods give results 6.5 times apart, so no single estimated fair value is trustworthy.
- annual growth the price requires-0.74%
- growth delivered historically-3.42%
- value with no growth at all$17.66
growth
revenue, 3 years -14.56%The pace has slowed
8.48%revenue, 5-year average
-14.56%revenue, 3-year average
31.02%of today's price depends on future growth
balance sheet and dividends
estimated rating ASolid balance sheet
Aestimated credit rating
4.47 yearsof operating profit to clear all debt
- net debt$62.75B
- dividend yield6.65%
- of returned capital goes to buybacks2.11%
arguments for and against
7 for · 6 againstWhat supports the case and what weakens it
Pro 7 arguments
- Dividend yield (trailing 12 months): 6.72%.Better than 94% of companies in the sector. Dividends paid over the past year against the current price.
- Price / floor value: 0.89x.Better than 89% of companies in the sector. Price against a conservative minimum valuation.
- Value at risk 95% (historical): 2.24%.Better than 86% of companies in the sector. The daily loss not exceeded on 95% of days.
4 more arguments
- Total shareholder yield: 5.17%.Better than 82% of companies in the sector. Dividends, buybacks and debt reduction taken together.
- Earnings power value vs price: 54.58%.Better than 79% of companies in the sector. What the company is worth if current profit stays flat forever, against its price.
- Stress test (composite): 81.9.Better than 73% of companies in the sector. Aggregate score across several simulated crisis scenarios.
- Beta: 0.61.Better than 72% of companies in the sector. How strongly the share moves when the market moves.
Against 6 arguments
- Free cash flow growth (5-year annual): -4.81%.Only 13% of companies in the sector do worse on this measure. Average yearly growth in free cash flow.
- Montier C-score (0–6): 4.Only 16% of companies in the sector do worse on this measure. Six warning signals about the quality of accounting.
- Net income growth (5-year annual): -3.24%.Only 20% of companies in the sector do worse on this measure. Average yearly growth in net income.
3 more arguments
- Earnings per share growth (5-year annual): -3.42%.Only 22% of companies in the sector do worse on this measure. Average yearly growth in earnings per share.
- Accruals ratio (Sloan): -1.87%.Only 22% of companies in the sector do worse on this measure. How much of reported profit is accounting only, rather than cash collected.
- Credit health score: 78.7.Only 27% of companies in the sector do worse on this measure. Composite score summarising the firm's ability to carry its debt.
what is left to decide
Middling quality
and a stretched price.
Neither the business nor the price stands out. This is a case decided on details, not on the big picture.
For this to work out, the growth rate would have to resume, not merely stabilise.
Disclosure (legal information) See details Hide
Analysis produced by einvestitii.ro, founder . We are not supervised by the Romanian Financial Supervisory Authority. This is not personalised investment advice. Fair values are estimates, not guaranteed prices.
- Calculated 11 August 2026
- Price used $25.60 (as of 10 June 2026)
- Estimated fair value $17.66 — an estimate dependent on assumptions (cost of capital, growth, terminal value). Not a price target. Confidence: Medie.
- Updates On every recalculation of the company fundamentals.
- Verdict changed no (score +0.2 against the previous assessment)
- Conflicts of interest We hold no positions in the instruments analysed and receive no payment from issuers for assessments. Pages may contain affiliate links to brokers, marked as such, which do not influence the scores.